Search results
Bristol Myers to pay $2.7 mln to settle Israel anti-competition charges - ET HealthWorld | Pharma
The Economic Times· 21 hours agoJerusalem: Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to...
Eisai and Bristol Myers cancel cancer ADC deal
BioPharma Dive· 23 hours agoThe Japan-based drugmaker said its U.S. partner’s “portfolio prioritization efforts” led to the termination. It will refund part of an upfront payment.
CAR-T landscape set to expand in 2024
Clinical Trials Arena· 32 minutes agoKey major players in this field are Novartis, Gilead, and Bristol Myers Squibb. Bristol Myers Squibb is one of the ...
BMS expands Krazati’s FDA label to include colorectal cancer
Clinical Trials Arena· 7 days agoThe US Food and Drug Administration (FDA) has approved Bristol Myers Squibb's (BMS) Krazati...
Vivos eyes human trials for radiation treatment gel with IDE submission
Clinical Trials Arena· 18 hours agoBig pharma has made plays for the space in the past year too, with Eli Lilly, Novartis and Bristol...
2seventy bio completes $40m haemophilia A program deal with Novo Nordisk
Pharmaceutical Technology· 5 days agoAbecma gained approval from the US Food and Drug Administration (FDA) in April 2024. An FDA...
AI and stable funding environments are catalysts for biotech assets
Pharmaceutical Technology· 5 days agoAs revenue growth is what drives biopharma share prices, what these big companies need are...
ASCO24: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC
Pharmaceutical Technology· 7 days agoThis potentially causes membrane damage in cancer cells, leading to selective necrosis of cancer...
ASCO24: Novartis’ Scemblix outperforms standard of care in CML
Pharmaceutical Technology· 7 days agoThe therapy also showed an MMR rate of 69.3% at 48 weeks, compared to an MMR of 40...
'$10 bn opportunity up for grabs in off patent drug market by 2029'
Business Standard India· 5 days agoAs many as 15 blockbuster drugs whose revenues worth $112 billion will be off-patented during 2023...
